Optimizing dendritic cell-based immunotherapy in multiple myeloma

被引:80
作者
Yi, Q
Desikan, R
Barlogie, B
Munshi, N
机构
[1] Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA
[2] Cent Arkansas Vet Med Ctr, Little Rock, AR USA
关键词
dendritic cells; idiotype; vaccination; subcutaneous; multiple myeloma;
D O I
10.1046/j.1365-2141.2002.03411.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vaccination with idiotype protein-pulsed dendritic cells (DCs) has been explored in multiple myeloma and the results have been disappointing. These studies used immature DCs, which are less potent at activating T cells and could differentiate to macrophages once the cytokines were withdrawn. After intravenous administration, DCs accumulate in the lungs and liver for up to 48 h, thus reducing their potential to migrate to lymphoid organs and interact with T cells. To improve the efficacy of DC vaccination in myeloma, we investigated the use of idiotype-pulsed mature DCs administered subcutaneously. Five patients (three IgG and two IgA myeloma) with stable partial remission following high-dose chemotherapy were enrolled. DC vaccines were administered three times at 2-week intervals at least 4 months post transplantation. Idiotype-specific T-cell responses, detected using enzyme-linked immunospot (ELISPOT) (four patients) and proliferation (two patients) assays, were elicited in four and anti-idiotypic B-cell responses in all five patients. The cytokine-secretion profile of activated T cells demonstrated a type-1 response. A 50% reduction in serum M-component was observed in one immunologically responding patient that persisted for 6 months and stable disease (for 6 months) resulted in the other three patients. The remaining patient without an immune response to the vaccination relapsed. No major side-effects were noted. Thus, subcutaneous administration of idiotype-pulsed mature DCs induced idiotype-specific T- and B-cell responses. Current efforts are geared towards optimizing the conditions of DC generation and administration, and the development of in vitro assays to monitor the cytotoxicity of the T cells.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
[31]   Dendritic cell-based immunotherapy: a basic review and recent advances [J].
João Constantino ;
Célia Gomes ;
Amílcar Falcão ;
Bruno Miguel Neves ;
Maria Teresa Cruz .
Immunologic Research, 2017, 65 :798-810
[32]   Dendritic cell-based vaccine: a promising approach for cancer immunotherapy [J].
K Tarte ;
B Klein .
Leukemia, 1999, 13 :653-663
[33]   Strategies to improve dendritic cell-based immunotherapy against cancer [J].
Song, SY ;
Kim, HS .
YONSEI MEDICAL JOURNAL, 2004, 45 :48-52
[34]   Dendritic cell-based active specific immunotherapy for malignant glioma [J].
Parajuli, Prahlad ;
Mathupala, Saroj ;
Mittal, Sandeep ;
Sloan, Andrew E. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (04) :439-448
[35]   Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity [J].
Hong, S. ;
Li, H. ;
Qian, J. ;
Yang, J. ;
Lu, Y. ;
Yi, Q. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 170 (02) :167-177
[36]   Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma [J].
Reina-Ortiz, Chantal ;
Giraldos, David ;
Azaceta, Gemma ;
Palomera, Luis ;
Marzo, Isabel ;
Naval, Javier ;
Villalba, Martin ;
Anel, Alberto .
CELLS, 2022, 11 (03)
[37]   Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells:: implications for dendritic cell-based immunotherapy [J].
Thumann, P ;
Lüftl, M ;
Moc, I ;
Bagot, M ;
Bensussan, A ;
Schuler, G ;
Jenne, L .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (06) :1128-1142
[38]   Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review [J].
de Oliveira, Jamile Barboza ;
Silva, Saulo Brito ;
Fernandes, Igor Lima ;
Batah, Sabrina Setembre ;
Herrera, Andrea Jazel Rodriguez ;
Cetlin, Andrea de Cassia Vernier Antunes ;
Fabro, Alexandre Todorovic .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[39]   Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer [J].
Ni, Ling .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[40]   Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy [J].
Reis, Edione C. ;
da Silva, Lais T. ;
da Silva, Wanessa C. ;
Rios, Alexandre ;
Duarte, Alberto J. ;
Oshiro, Telma M. ;
Crovella, Sergio ;
Pontillo, Alessandra .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) :1995-2002